| Literature DB >> 23626564 |
Yuichi Kinoshita1, Kosho Takasu, Takashi Yuri, Kastuhiko Yoshizawa, Yuko Emoto, Airo Tsubura, Nobuaki Shikata.
Abstract
The diffuse sclerosing variant of papillary thyroid carcinoma (DSV-PTC) is a relatively rare tumor. We herein report the case of young woman with DSV-PTC who developed cervical lymph node recurrence 7 years after the initial surgery. A 15-year-old female patient with no medical or family history of thyroid tumors developed a thyroid neoplasm in the right lobe. Right thyroidectomy and regional lymphadenectomy were performed, and the tumor was diagnosed as DSV-PTC. She was followed up as an outpatient. Seven years after the surgery, cervical lymph node recurrence developed. On microscopic examination, the thyroid tumor showed a papillary growth pattern with numerous psammoma bodies and distinct fibrosis. Immunohistochemically, the tumor cells were estrogen receptor and progesterone receptor positive with reduced membranous expression of E-cadherin and were intermingled with S-100-positive dendritic/Langerhans cells. DSV-PTC is characterized by a strong tendency for invasion and metastasis. Thus, accurate diagnosis is clinically important, and a morphological and immunohistochemical understanding of DSV-PTC is necessary.Entities:
Keywords: Diffuse sclerosing variant of papillary thyroid carcinoma; E-cadherin; Estrogen receptor; Immunohistochemistry; Progesterone receptor; S-100
Year: 2013 PMID: 23626564 PMCID: PMC3636970 DOI: 10.1159/000350784
Source DB: PubMed Journal: Case Rep Oncol ISSN: 1662-6575
Fig. 1Ultrasonographic findings. Right thyroid lobe enlargement and numerous microcalcifications can be seen.
Fig. 2Cut surface of the right thyroid lobe. An indistinct diffuse lesion with microcalcifications can be seen.
Fig. 3DSV-PTC. a Growing papillary tumor with remarkable fibrosis and lymphocytic infiltration can be seen. HE. ×100. b Note the numerous psammoma bodies. HE. ×400. c Scattered foci of squamous metaplasia can be seen. HE. ×400. d Characteristic nuclear features of PTC. Nuclear grooves and intracytoplasmic inclusion body (inset) can be seen. HE. ×400.
Fig. 4Tumor cells are positive for ER (a), PgR in the nucleus (b), and E-cadherin in the cytoplasm (c). d Dendritic/Langerhans cells are positive for S-100 protein. Immunohistostaining. ×400.
Immunohistochemical results
| Antibody | Source | Clone | Dilution | Result | |
|---|---|---|---|---|---|
| papillary cell carcinoma | metastatic cells | ||||
| Epithelial membrane antigen | DakoCytomation, Glostrup, Denmark | E29 | 1:100 | cytoplasm | cytoplasm |
| Cytokeratin 7 | Ventana Medical Systems, Tucson, Ariz., USA | SP52 | prediluted | cytoplasm | cytoplasm |
| Cytokeratin 20 | Ventana Medical Systems | SP33 | prediluted | – | – |
| Thyroglobulin | DakoCytomation | polyclonal | prediluted | cytoplasm | cytoplasm |
| E-cadherin | Takara Bio Inc., Otsu, Japan | HECD-1 | 1:100 | cytoplasm | cytoplasm |
| β-catenin | Becton Dickinson, N.J., USA | 14 | 1:500 | membrane | membrane (partially) |
| c-kit | Nichirei Biosciences, Tokyo, Japan | polyclonal | prediluted | – | – |
| p63 | Nichirei Biosciences | 4A4 | prediluted | nucleus (partially) | partially |
| Bcl-2 | SIGNET, Calif., USA | 124 | prediluted | – | – |
| Wilms‘ tumor antigen 1 | Novocastra, Newcastle upon Tyne, UK | 6F-H2 | prediluted | – | – |
| CD56 | Nichirei Biosciences | 1B6 | prediluted | – | – |
| Chromogranin A | Diagnostic BioSystems, Calif., USA | LK2H10 | prediluted | – | – |
| Synaptophysin | DakoCytomation | SY38 | 1:20 | – | – |
| S-100 protein | Nichirei Biosciences | polyclonal | prediluted | – | – |
| ER | Nichirei Biosciences | SP1 | prediluted | nucleus | – |
| PgR | Nichirei Biosciences | A9621A | prediluted | nucleus | – |
| Androgen receptor | Novocastra | AR27 | 1:50 | – | – |
| Ki-67 index | DakoCytomation | MIB1 | prediluted | <1% | <1% |
| p53 | Novocastra | Do-7 | 1:50 | <1% | <1% |
MACIS score
| 1 | +3.1 (if age <40 years) or 0.08 × age (if age ≥40 years) |
| 2 | +0.3 × tumor size (cm, maximum diameter) |
| 3 | +1 if not completely resected |
| 4 | +1 if locally invasive |
| 5 | +3 if spread distantly |
| Survival score is 1 + 2 + 3 + 4 + 5 (20 years after surgery): | |
| <6 = 99% | |
| 6–6.99 = 89% | |
| 7–7.99 = 56% | |
| ≥8 = 24% | |